Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$31.16
$26.01
$19.05
$32.56
$3.81B0.723.12 million shs4.13 million shs
Microsoft Corporation stock logo
MSFT
Microsoft
$409.43
+1.0%
$397.84
$356.28
$555.45
$3.01T1.135.16 million shs27.01 million shs
NIO Inc. stock logo
NIO
NIO
$6.27
-4.2%
$6.00
$3.34
$8.02
$15.03B0.9730.91 million shs36.62 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
0.00%-0.03%+18.98%+28.07%+33.16%
Microsoft Corporation stock logo
MSFT
Microsoft
+1.04%-2.73%+4.17%+2.02%-9.61%
NIO Inc. stock logo
NIO
NIO
-4.28%+6.46%-4.79%+26.69%+52.43%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$31.16
$26.01
$19.05
$32.56
$3.81B0.723.12 million shs4.13 million shs
Microsoft Corporation stock logo
MSFT
Microsoft
$409.43
+1.0%
$397.84
$356.28
$555.45
$3.01T1.135.16 million shs27.01 million shs
NIO Inc. stock logo
NIO
NIO
$6.27
-4.2%
$6.00
$3.34
$8.02
$15.03B0.9730.91 million shs36.62 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
0.00%-0.03%+18.98%+28.07%+33.16%
Microsoft Corporation stock logo
MSFT
Microsoft
+1.04%-2.73%+4.17%+2.02%-9.61%
NIO Inc. stock logo
NIO
NIO
-4.28%+6.46%-4.79%+26.69%+52.43%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
2.88
Moderate Buy$32.173.23% Upside
Microsoft Corporation stock logo
MSFT
Microsoft
2.85
Moderate Buy$560.8836.99% Upside
NIO Inc. stock logo
NIO
NIO
2.38
Hold$6.808.54% Upside

Current Analyst Ratings Breakdown

Latest MSFT, NIO, and CPRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Reiterated RatingOutperform$575.00
5/13/2026
Microsoft Corporation stock logo
MSFT
Microsoft
UpgradeBuy$485.00
5/8/2026
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
DowngradeBuyNeutral$35.00 ➝ $31.50
5/7/2026
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
DowngradeOutperformMarket Perform
5/7/2026
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
Set Price Target$32.00
5/7/2026
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
DowngradeStrong-BuyHold
5/7/2026
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
DowngradeOverweightEqual Weight
5/7/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Lower Price Target$678.00 ➝ $573.00
5/7/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Reiterated RatingBuy
5/6/2026
Microsoft Corporation stock logo
MSFT
Microsoft
Boost Price TargetBuy$595.00 ➝ $680.00
5/5/2026
Microsoft Corporation stock logo
MSFT
Microsoft
DowngradeMarket Perform
(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$588.99M6.47$2.92 per share10.66$8.27 per share3.77
Microsoft Corporation stock logo
MSFT
Microsoft
$281.72B10.80$18.48 per share22.15$55.78 per share7.34
NIO Inc. stock logo
NIO
NIO
$12.51B1.15N/AN/A$0.26 per share24.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$214.33M$1.7417.9110.120.9137.08%35.76%31.31%N/A
Microsoft Corporation stock logo
MSFT
Microsoft
$101.83B$16.8024.3721.221.4639.34%31.94%18.47%7/29/2026 (Estimated)
NIO Inc. stock logo
NIO
NIO
-$2.14B-$0.97N/AN/AN/A-17.21%-924.56%-13.91%5/21/2026 (Estimated)

Latest MSFT, NIO, and CPRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2026Q1 2026
NIO Inc. stock logo
NIO
NIO
-$0.0750N/AN/AN/A$3.65 billionN/A
4/29/2026Q3 2026
Microsoft Corporation stock logo
MSFT
Microsoft
$4.06$4.27+$0.21$4.27$81.44 billion$82.89 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/AN/AN/AN/AN/A
Microsoft Corporation stock logo
MSFT
Microsoft
$3.640.89%+10.24%21.67%23 Years
NIO Inc. stock logo
NIO
NIO
N/AN/AN/AN/AN/A

Latest MSFT, NIO, and CPRX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/10/2026
Microsoft Corporation stock logo
MSFT
Microsoft
quarterly$0.910.9%5/21/20265/21/20266/11/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/A
7.10
5.82
Microsoft Corporation stock logo
MSFT
Microsoft
0.08
1.28
1.27
NIO Inc. stock logo
NIO
NIO
2.08
0.98
0.87

Institutional Ownership

CompanyInstitutional Ownership
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
79.22%
Microsoft Corporation stock logo
MSFT
Microsoft
71.13%
NIO Inc. stock logo
NIO
NIO
48.55%

Insider Ownership

CompanyInsider Ownership
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
10.40%
Microsoft Corporation stock logo
MSFT
Microsoft
0.03%
NIO Inc. stock logo
NIO
NIO
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
80122.38 million109.65 millionOptionable
Microsoft Corporation stock logo
MSFT
Microsoft
228,0007.43 billion7.43 billionOptionable
NIO Inc. stock logo
NIO
NIO
35,0322.30 billion2.27 billionOptionable

Recent News About These Companies

NIO stock faces a big test ahead of earnings
NIO’s Firefly Australia Entry Tests Premium EV Growth Story
NIO (NIO) to Release Earnings on Thursday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Catalyst Pharmaceuticals stock logo

Catalyst Pharmaceuticals NASDAQ:CPRX

$31.16 0.00 (0.00%)
Closing price 05/14/2026 04:00 PM Eastern
Extended Trading
$31.16 +0.00 (+0.00%)
As of 05:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Microsoft stock logo

Microsoft NASDAQ:MSFT

$409.43 +4.22 (+1.04%)
Closing price 05/14/2026 04:00 PM Eastern
Extended Trading
$410.32 +0.89 (+0.22%)
As of 06:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Microsoft Corporation develops and supports software, services, devices and solutions worldwide. The Productivity and Business Processes segment offers office, exchange, SharePoint, Microsoft Teams, office 365 Security and Compliance, Microsoft viva, and Microsoft 365 copilot; and office consumer services, such as Microsoft 365 consumer subscriptions, Office licensed on-premises, and other office services. This segment also provides LinkedIn; and dynamics business solutions, including Dynamics 365, a set of intelligent, cloud-based applications across ERP, CRM, power apps, and power automate; and on-premises ERP and CRM applications. The Intelligent Cloud segment offers server products and cloud services, such as azure and other cloud services; SQL and windows server, visual studio, system center, and related client access licenses, as well as nuance and GitHub; and enterprise services including enterprise support services, industry solutions, and nuance professional services. The More Personal Computing segment offers Windows, including windows OEM licensing and other non-volume licensing of the Windows operating system; Windows commercial comprising volume licensing of the Windows operating system, windows cloud services, and other Windows commercial offerings; patent licensing; and windows Internet of Things; and devices, such as surface, HoloLens, and PC accessories. Additionally, this segment provides gaming, which includes Xbox hardware and content, and first- and third-party content; Xbox game pass and other subscriptions, cloud gaming, advertising, third-party disc royalties, and other cloud services; and search and news advertising, which includes Bing, Microsoft News and Edge, and third-party affiliates. The company sells its products through OEMs, distributors, and resellers; and directly through digital marketplaces, online, and retail stores. The company was founded in 1975 and is headquartered in Redmond, Washington.

NIO stock logo

NIO NYSE:NIO

$6.26 -0.28 (-4.20%)
Closing price 05/14/2026 03:59 PM Eastern
Extended Trading
$6.20 -0.06 (-1.04%)
As of 06:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NIO Inc. designs, manufactures, and sells electric vehicles in the People's Republic of China. The company is also involved in the manufacture of e-powertrain, battery packs, and components; and racing management, technology development, and sales and after-sales management activities. In addition, it offers power solutions for battery charging needs; and other value-added services. The company was formerly known as NextEV Inc. and changed its name to NIO Inc. in July 2017. NIO Inc. was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.